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Introduction
Staphylococcus aureus is a gram positive pathogen and the most 
common cause of skin and soft-tissue infection (SSTI) in the 
world. A study done in 2008-2009, spanning more than nineteen 
European countries and more than 3000 cases of complicat-
ed skin and soft tissue infections (cSSTI), found that about one 
third of these cases were due to S. aureus (Russo, et al., 2016). 
S. aureus is responsible for common skin infections such as im-
petigo, cellulitis, folliculitis, carbuncles, abscess, pyomyositis, and 
necrotizing fasciitis, as well as more deep-rooted infections that 
lead to blood stream infections, nosocomial pneumonia, and 
infection of wounds and surgical sites (Popovich, et al., 2008). 
S. aureus is so prevalent that about 25% of humans are consis-
tent carriers of this microorganism, while 50% are observably 
intermittent carriers. Colonies of S. aureus can be found in the 
anterior nares and other areas of skin throughout the body.
Penicillin was the first antibiotic used to treat S. aureus infec-
tions; however, within a few years S. aureus developed resistance 
to this “miracle drug”. A specific strain of S. aureus started to 
produce an enzyme capable of destroying penicillin, called pen-
icillinase. The plasmid that produced the penicillinase quickly 
spread among the different strains of S. aureus. To combat this 
new development, methicillin, which is a semisynthetic β-lact-
amase-resistant penicillin, was created in 1959. After only two 
short years, the first case of methicillin-resistant staphylococcus 
aureus (MRSA) was reported. This case of bacterial resistance 
was the result of a more complex mechanism than found in 
the penicillin resistant strain of S. aureus. Methicillin works by 
blocking the protein penicillin binding protein (PBP), found in S. 
aureus that is associated with the construction and maintenance 
of the cell wall. Instead of using these PBP proteins, resistant 
strains of S. aureus acquired a new protein, PBP2a, which has the 
same function as PBP but is not susceptible to methicillin. PBP2a 
is encoded by the gene mecA, located on the chromosome, 
unlike the penicillinase gene which is found on the plasmid. This 
mecA gene is a distinguishing characteristic of MRSA and the 
presence of PBP2a means that S. aureus is resistant not only 
to methicillin, but to all β-lactam antibiotics, including synthetic 
penicillin, cephalosporin and carbapenem (Mastofsky, et al, 2011; 
Pantosti, Veniti, 2009; Popovich, Hota,2008).
HA-MRSA
MRSA has become a worldwide problem and is common 
throughout hospitals as well as smaller healthcare facilities. 
Since its origins in the 1960s, the spread of healthcare-associ-
ated MRSA has become a public health concern (Mastofsky et 
al, 2011; Pantosti, Veniti, 2009). The common strains of MRSA 
found today originated from a few clones that developed in-
dependently of each other (Gardam, 2000). MRSA is spread by 
direct contact and most often in a healthcare setting where 
contamination can spread through the hands of healthcare pro-
viders (Okado et al, 2016). This spread of infection has led to 
the definition of HA-MRSA which is an annotation for health-
care-associated MRSA or for hospital-acquired MRSA. Patients 
with compromised immune system or those that have had ex-
tended hospital stays are more susceptible to the contraction of 
MRSA. In addition, use of antibiotics and undergoing surgery are 
factors that can contribute to MRSA infection. Once a patient 
has acquired HA-MRSA it is extremely difficult to eradicate and 
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the person can be a carrier for an extended period of time 
(Gardam 2000). A patient can be a carrier for HA-MRSA for 
longer than six months, long after his discharge from the hospi-
tal (Pantosti, Veniti, 2009). 
In order to reduce the prevalence of HA-MRSA and to stop 
the spread of this nosocomial pathogen, hospitals take on two 
different approaches. The first recommendation is prevention 
based and includes barrier precautions, hand washing and en-
vironmental cleaning for MRSA patients. The second approach 
is an implementation of an antibiotic stewardship program. The 
purpose of the program is to control antibiotic prescribing in 
order to reduce the adverse effects of antibiotics, such as drug 
resistance and more specifically decreasing the spread of infec-
tion caused by multi-drug resistant bacteria. A 10-year program 
implemented in Saint-Joseph Hospital in Paris, France focused 
on applying a combination of these two aspects to decrease the 
prevalence of HA-MRSA found in their hospital. The program, 
implemented from 2000-2009, showed an 84% decrease in HA-
MRSA colonization throughout the hospital. Researchers found 
that there was an increase in the use of alcohol based hand rubs 
(ABHR) from 6.8 L to 27.5 L per 1000 patient-days. Additionally, 
antibiotic use, measured with the Defined Daily Dose (DDD) 
per 1000 patient-days decreased by 31%. The implementation 
of this program and its results were significant in that it was 
conducted in a region known to be endemic for MRSA. From 
2000-2009, France had MRSA rates greater than 25%, an alarm-
ingly high rate (Chalfine et al, 2012).
CA-MRSA
In the 1990s a new strain of MRSA emerged. Known as com-
munity-associated methicillin resistant staphylococcus aureus 
(CA-MRSA) This new epidemiology has the capability of causing 
infections in otherwise healthy individuals who have had no pre-
vious exposure to a healthcare setting. These reported cases of 
CA-MRSA have statistically worse clinical outcomes than those 
of HA-MRSA (Mostofsky et al, 2011; Pantosti,Veniti, 2009). CA-
MRSA is a more infectious form of S. aureus than HA-MRSA and 
can carry the genes that encode Panton-Valentine leucocidin 
(PVL) which is “associated with tissue necrosis and a greater 
severity of disease” (Russo et al, 2016). However, in most cases 
CA-MRSA causes skin and soft tissue infections (SSTI) such 
as furuncles, abscesses, impetigo, and cellulitis (Pantosi,Veniti, 
2009). CA-MRSA is the most common cause for patients pre-
senting with SSTI in emergency departments around the United 
States (Albrecht et al., 2015),
CA-MRSA has a number of distinguishing characteristics that 
differentiate it from HA-MRSA. Firstly, CA-MRSA, unlike HA-
MRSA, is vulnerable to most non-β-lactam antibiotics and con-
tains what is known as SCCmec element of type IV and type 
V. SCCmec stands for staphylococcal cassette chromosome 
mec and is the mobile genetic element for S. aureus that is 
responsible for its resistance to methicillin and other β-lact-
am antibiotics. This SCCmec element is encoded by the gene 
mecA and is divided into subtypes I-VIII (The Working Group 
etc., 2009). Conversely, HA-MRSA is multidrug-resistant to 
non-β-lactam antibiotics and contains SCCmec type I, II, III. A 
second difference, as mentioned above, is that CA-MRSA con-
tains PVL, which is a strong virulence factor (Mostofsky et al, 
2011; Pantosti,Veniti, 2009). 
With the growing number of MRSA cases reported each year, 
the clearly defined lines between HA-MRSA and CA-MRSA are 
being blurred. Asymptomatic colonization of MRSA can persist 
for years and a HA-MRSA can be easily misconstrued for CA-
MRSA. Cases have been reported of community-onset HA-
MRSA, as well as nosocomial CA-MRSA infections (Mostofsky 
et al, 2011). The definitions abound as to how to clearly classify 
and differentiate between HA-MRSA and CA-MRSA. There are 
many uncertainties as to how to define prior hospitalization and 
length of time since hospitalization. This question is crucial as it 
determines if one is still a carrier of MRSA or not. The common 
definition of prior hospitalization is “hospitalization within six 
months to one year of current admission”. Sometimes, MRSA 
acquired from long term care facilities and nursing homes is 
not considered healthcare associated, but rather CA-MRSA, 
skewing the statistics (Gardam,2009). One way to differentiate 
between the two strains it to test the isolate’s susceptibility to 
non-β-lactam antibiotics, as this is one key difference between 
HA-MRSA and CA-MRSA (Popovich et al, 2008).  
There are many different treatment options available to treat 
MRSA infections, including incision and drainage, oral antibiotics, 
parenteral antibiotics, and topical therapies. More than one mode 
of therapy can be used. Treatment options can be administered 
on both an inpatient and outpatient basis (Popovich et al, 2008).
The purpose of this paper is to review some of the current and 
leading parenteral and oral treatment options used to best treat 
SSTIs caused by both HA-MRSA and CA-MRSA. It will explore 
and compare different antibiotics, their uses, benefits and side 
effects in an effort to understand the most effective way to treat 
MRSA.
Methods
This study was performed through the analyzation of various 
original and peer reviewed articles which were accessed using 
databases such as the Touro Database, PubMed, and Google 
Scholar. The research collected in this study was used to under-
stand MRSA, its effects and the best way to treat it when found 




There are many different treatment options for MRSA that are 
currently in use or in development. Some are administered oral-
ly or parenterally, while others are administered topically. 
Incision and Drainage
The most important part in the treatment of complicated SSTI 
(cSSTI) is the incision and drainage of the infection site. This 
procedure is common in the case of furuncle, soft tissue ab-
scesses and other purulent SSTI. An estimated 80% of patients 
presenting in the emergency departments with acute, purulent 
SSTI require drainage. Most patients with infections caused by 
CA-MRSA are cured via incision and drainage alone and do not 
require any antibiotics. Thus, incision and drainage, where ap-
propriate, is the first step to treating cSSTI caused by MRSA 
(Ruhe et al., 2007; Stryjewski et al., 2008). 
However, there is still much to learn regarding the effective-
ness of incision and drainage of infection sites. A study done on 
children with SSTI, with an infected site of greater than 5 cm, 
showed that pediatric patients are more likely to experience 
failure of incision and drainage alone and antibiotic therapy is 
usually necessary. Additionally, patients with other risk factors 
such as systemic illness, comorbidities, as well as multiple areas 
of SSTI are more likely to need antibiotic therapy in addition to 
or in place of incision and drainage (Popovich et al., 2008). 
Vancomycin
Vancomycin is the standard drug used today to treat SSTI 
caused by MRSA (Stryjewski et al., 2008). Since its introduction 
in 1958, it has been used to combat gram positive bacteria with 
great success. Vancomycin is administered parenterally on an 
inpatient basis. Vancomycin, a glycopeptide, works against MRSA 
by inhibiting the bacteria’s cell wall synthesis. It interacts with a 
peptide precursor of the peptidoglycan at an important site of 
attachment and thereby inhibits peptidoglycan polymerase and 
transpeptidation mechanisms.  Penicillin is also bactericidal by 
hindering biosynthesis of cell wall; however, vancomycin inhibits 
an earlier stage of the peptidoglycan synthesis thereby eliminat-
ing cross-resistance (Wilhelm et al., 1999).
The clinical practice guidelines set by the Infectious Diseases 
Society of America states that the recommended dose for the 
average adult with normal renal function for intravenous van-
comycin is 15-20mg/kg/dose every 8-12 hours. Dosage amount 
should not exceed 2000 mg regardless of a patient’s weight. 
For more serious cases, in which a patient is systemically ill and 
has a suspected MRSA infection, the dosage level may be ele-
vated to 25-30 mg/kg/dose. However, in such a case, one must 
be cautious for red man syndrome, a reaction associated with 
a high dosage of vancomycin that can cause anaphylaxis. As a 
precaution, infusion time can be lengthened to two hours and 
an antihistamine can be administered prior to the loading dose. 
Antibiotics can be administered on an empirical basis until culture 
results are obtained (Liu et al., 2011). For patients who have prob-
lems with renal function, careful monitoring should be ensured 
while administering vancomycin, as vancomycin can sometimes 
be associated with nephrotoxicity (Wilhelm et al., 1999). 
As with the development of resistance to β-lactam antibiotics 
which led to the new subset of S. aureus, specifically MRSA, new 
reports have come out of vancomycin resistance. The levels of 
resistance range from intermediate susceptibility to full resis-
tance of vancomycin (Pantosti et al., 2009). These new strains of 
S. aureus resistant to vancomycin are known as vancomycin-in-
termediate S. aureus (VISA) and as vancomycin-resistant S. aureus 
(VRSA) (Popovich et al., 2008). There is even a third category of 
vancomycin resistant bacteria known as hetero-VISA, that seems 
to be vancomycin susceptible when routinely tested, but contain 
a minority of cells that have intermediate vancomycin suscepti-
bility. Upon exposure to vancomycin, these hetero-VISA bacteria 
can multiply in number and spread (Pantosti et al., 2009). 
VRSA developed from a prolonged use of vancomycin in re-
sponse to chronic MRSA infection. Over time, the bacteria 
changed from MRSA to VRSA by the plasmid exchange of vanA, 
the gene for vancomycin resistance, possibly from a co-infect-
ing vancomycin-resistant enterococcus (Pantosti et al., 2009). 
A minimum inhibitory concentration (MIC) to vancomycin has 
been observed nationwide in MRSA isolates. This phenomenon, 
known as the MIC creep, has led to the lowering of the MIC 
breakpoint for vancomycin in 2006 to ≤ 2 µg/ml for suscepti-
ble, 4-8 µg/ml for intermediate, and ≥16 µg/ml for resistant. As 
a result, higher dosage amounts are being recommended for 
therapy, yet there is no substantial data to prove its efficacy and 
a higher dosage may cause greater toxicity, especially nephro-
toxicity (Popovich et al., 2008). 
S. aureus that displays a decrease in vancomycin susceptibility 
generally has phenotypic features that are different than the 
strains of both original S. aureus and MRSA. The main phenotyp-
ic change of vancomycin-susceptible S. aureus (VSSA) to cause 
resistance is a general thickening of the cell wall. Involved in this 
alteration of cell wall structure is an overexpression of PBP2 
and PBP2a, increased level of abnormal muropeptide protein, 
increased amount of D-alanyl-D-alanine residue, and reduction 
of peptidoglycan cross-linkage (Sirichoat et al., 2016).
Linezolid
Many test results have shown Linezolid to be a comparable drug, 
in terms of results, to vancomycin. Linezolid is an oxazolidinone 
antibiotic that was first discovered in the 1990s and approved 
37
Treatment Options for Skin and Soft Tissue Infections
for use in standard medicine in 2000 (Dumitrescu, Lina., 2014). 
Linezolid is the first antibiotic of this class to be brought to 
market. Oxazolidinone represents a new systemic antimicrobial 
class.  Linezolid works by blocking protein function in the cell. 
It binds to the 50s subunit of the pathogenic cell which pre-
vents it from complexing with the 30s subunit, mRNA, initiation 
factors, and formylmethionyl-tRNA. This inhibition prevents 
the formation of the protein initiation complex, preventing 
the translation step of protein synthesis. Other drugs that are 
classified as protein synthesis inhibitors, such as macrolides and 
tetracyclines, have different mechanisms, as each allows the 
process of mRNA translation to begin, while stopping peptide 
elongation. This mode of action of linezolid seems to work par-
ticularly well against staphylococcal infections. Additionally, its 
target site is unique and does not interfere with the mechanism 
for other protein synthesis inhibitors. Linezolid is bacteriostatic 
(Livermore, 2003). 
Reported cases of linezolid resistance have been rare and a 
number of reasons for the low level of resistance have been 
proposed. First, linezolid is an entirely synthetic compound, so 
it is unlikely that naturally occurring mechanisms of resistance, 
such as those found in antibiotic producing organisms will be 
employed. Second, oxazolidinones inhibit ribosomal protein 
synthesis while other antibiotics of similar ribosomal protein 
synthesis mechanisms do not propose cross-resistance to 
linezolid. Additionally, linezolid acts by binding to the 23s rRNA 
of the 50s ribosomal subunit. There are multiple copies of the 
gene that code for 23s rRNA in each cell. For resistance to 
occur, mutations would be necessary in each of the copies of 
the gene. Because of the fear of resistance, caution should be 
employed when there is a long and repeated use of antibiotics 
(Meka, Gold, 2004).  
Linezolid is administered either intravenously or orally. It has 
100% oral bioavailability and therefore allows for rapid transi-
tion from parenteral form to an oral one, possibly resulting in 
early discharge from the hospital. This can result in decreased 
length of stay and a decrease in overall cost of treatment. MRSA 
can be treated with oral linezolid exclusively. Outcomes were 
the same for patients treated only with oral linezolid compared 
to intravenous vancomycin despite the difference in routes of 
administration and antibiotic (Dumitresu, Lima, 2014; Weiglet 
et al., 2005). Standard dosage of linezolid is 600 mg every 12 
hours. For uncomplicated SSTI the recommended dose is 400 
mg every 12 hours. Because of its 100% bioavailability, dos-
age amount is not dependent on the route it is administered 
(Moellering 2003). 
Linezolid can cause some minor side effects, including gastro-
intestinal discomfort such as nausea, vomiting and diarrhea, 
and dermatological effects, like rash and itchiness. Most re-
ported adverse effects ceased with the cessation of therapy. 
When therapy exceeded 14 days, 12.6% of patients studied, 
experienced hematologic effects such as decreases in platelet 
count, hemoglobin level, hematocrit and white blood cell count 
(Birmingham et al., 2003). Linezolid can also cause reversible 
myelosuppression when administration of antibiotics exceeds 
14 days (Weigelt et al., 2005). 
In clinical studies linezolid has performed comparably to vanco-
mycin in treating cSSTI caused by MRSA, with possible advantage. 
A study showed that “linezolid [was] superior … to vancomycin 
in the MRSA subset. The difference between linezolid and vanco-
mycin results was most dramatic in patients with abscesses and 
surgical-site infections caused by MRSA”. Linezolid is more effec-
tive in treating SSTI caused by MRSA due to the enhanced pen-
etration of linezolid into the skin and tissue (Weigelt et al.2005). 
Linezolid has also shown to be less nephrotoxic than vancomycin 
(Dumitrescu et al., 2014). In a study comparing the treatment of 
cSSTI caused by MRSA with linezolid and vancomycin in diabetic 
and non-diabetic patients, similar results indicated no significant 
difference in therapy of diabetic patients. However, for non-dia-
betic patients, results showed a greater success rate for patients 
treated with linezolid (Lipsky et al., 2011). Other studies have 
shown no significant benefit of using linezolid over vancomycin. 
Szczypinska et al. claims that by examining length of stay (LOS) 
as the determining factor of efficacy of an antibiotic, no signifi-
cant difference was found between vancomycin and linezolid. As 
of now, linezolid is used as a secondary choice to vancomycin in 
cases of vancomycin resistance, despite the proven success and 
efficacy of linezolid in treating MRSA, in order to prevent the rise 
of linezolid resistance (2013).        
Daptomycin
Daptomycin is another viable antibiotic for the treatment of 
SSTI caused by MRSA that was brought to market in 2003 
(Popovich et al., 2008). Cell death is caused by rapidly depolar-
izing the bacterial membrane. The lipophilic tail of daptomycin, 
a cyclic lipopeptide compound, inserts itself into the bacterial 
cytoplasmic membrane, in this case MRSA, and causes a rapid 
depolarization of the membrane. This ultimately leads to a loss 
of DNA, RNA, and protein synthesis. Daptomycin is bactericidal 
at all of the bacterial growth stages, including the stationary 
phase (Aikawa et al., 2013; Gonzalez-Ruiz et al., 2016; Seaton, 
2008).
Daptomycin resistance is rare but is a growing concern in the 
healthcare field (Hayden et al., 2005). The mechanism of resis-
tance is unknown but it has been suggested that the mechanism 
of resistance may be due to irregular dltA transcription factor 
which “may result in a change of the bacterial cell membrane 
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fluidity and therefore lead to a reduced affinity of daptomycin to 
its target site” (Gonzalez-Ruiz et al., 2016). It has been hypoth-
esized that the mechanism for daptomycin resistance is similar 
to that of vancomycin by VISA. Daptomycin is similar in size and 
weight to vancomycin and may not be able to penetrate the cell 
wall to reach the cell membrane, which daptomycin interacts 
with, if the cell wall thickens as it does in VISA. Daptomycin 
would never have the opportunity to reach the bacterial cy-
toplasmic membrane in the face of such an obstacle, resulting 
in daptomycin resistance (Cui et. al. 2006). Resistance to dap-
tomycin without previous exposure has so far proved to be 
extremely rare, with an observation of only 0.04% of 10,000 
cultures tested shown to have an MIC of 2 µg (Gonzalez-Ruiz 
et al., 2016). 
The recommended dose of daptomycin to treat cSSTI is 4 mg/kg/
day to be administered parenterally with a 30-minute IV infusion. 
Course of treatment for daptomycin is 7-14 days. Daptomycin 
use has not been approved for pediatric patients (Gonzalez-Ruiz 
et al., 2016; Seaton, 2008). Daptomycin is administered only once 
daily to reduce the risk of elevated creatine phosphokinase (CPK) 
levels and skeletal muscle toxicity. Elevated CPK levels were re-
solved upon discontinuation of daptomycin treatment. The most 
common adverse effects reported are constipation, nausea, and 
headache (Gonzalez-Ruiz et al., 2016).    
In some cases, such as difficult-to-treat infections like recurrent 
MRSA due to vancomycin resistance, a higher dosage of dapto-
mycin (≥6 mg/kg/day) may be recommended. A higher dosage 
of daptomycin would allow for rapid clearing of bacteria and 
would lower the risk for emerging resistance. Daptomycin has 
also been used in combination with other antimicrobial thera-
pies to prevent the rise of resistance. Such combination ther-
apies should be considered for patients who are at high risk 
of developing resistance to daptomycin alone. Daptomycin and 
linezolid combination therapy was synergistic in its effect and 
was bactericidal for MRSA. Daptomycin has also been used with 
rifampin, trimethoprim-sulfamethoxide, fosfomycin, and tigecy-
cline (Gonzalez-Ruiz et al., 2016). 
Many studies have been performed measuring the efficacy of 
daptomycin compared with that of vancomycin. Most show 
daptomycin and vancomycin to be comparable and a selec-
tion should be made based upon physician and patient pref-
erence, resistance factors and economic cost/ benefit analysis 
(Gonzalez-Ruiz et al., 2016; Kauf et al. 2015). Patients treated 
with daptomycin showed a greater probability of clinical suc-
cess by day 2 than those receiving vancomycin therapy, however 
length of stay for patients from both antibiotic groups averaged 
to be the same- four days. Vancomycin is also significantly cheap-
er than daptomycin (Kauf et al. 2015).  
Clindamycin
Clindamycin is especially useful in treating MRSA in an outpatient 
setting (Frei et al., 2010). Clindamycin is a lincosamide drug and 
belongs to the class of antibiotics known as macrolides, lincos-
amides and streptogramin B (MLS). Although similar in function 
to macrolides, lincosamides and streptogramin B are structurally 
different. Clindamycin works by binding to the large ribosomal 
subunit, which is the center responsible for catalyzing the for-
mation of peptide bonds during protein elongation. Clindamycin 
blocks this ribosomal tunnel, allowing peptide elongation to con-
tinue until it reaches a point of steric hindrance caused by the 
clindamycin. This inhibition will lead to eventual dissociation of the 
peptidyl-tRNA from the ribosome. Once a peptide has reached 
a certain length on the ribosome, clindamycin loses its ability to 
inhibit protein synthesis (Tenson et al., 2003). 
Resistance to clindamycin therapy is a cause for concern. The 
resistance mechanism involves modification of the drug binding 
site on the ribosome. The mechanism is the same for all MSL 
antibiotics, and is known as MSLB resistance. MSL drugs bind 
to the 23s rRNA-binding site. The erm gene is responsible for 
the methylation of the 23s rRNA-binding site. In the presence 
of the erm gene, resistance can be expressed constitutively as 
well as when induced into production. Because of the presence 
of the erm gene, resistance can occur during the course of clin-
damycin therapy (Lewis II et al., 2005; Popovich et al., 2008). 
In testing for clindamycin resistance, MRSA strains may appear 
susceptible, but can later develop resistance. To test for induc-
ible resistance, a D-zone test is used. This a double-disk diffusion 
test in which two disks, a clindamycin disk and an erythromycin 
disk are placed on a plate growing S. aureus. The strain is induc-
ible resistant if the zone of inhibition around the clindamycin 
disk facing the erythromycin disk is blunted, forming a D shape. 
Rates of inducible clindamycin resistance varies by region in the 
United States. Use of clindamycin should be determined by local 
rates (Popovich et al., 2008). 
Clindamycin can be administered parenterally or orally for SSTI. 
When administered intravenously, the appropriate dosage is 600 
mg every 8 hours. For oral administration, patients should be 
given 300-450 mg four times daily. Courses of treatment range 
from 10-14 days (Popovich et al., 2008). Clindamycin has a 90% 
oral bioavailability and can penetrate well into skin and skin 
structure. It is also less costly than some newer drugs used to 
treat SSTI caused by MRSA (Lewis II et al., 2005). Clindamycin 
may also inhibit the PVL gene that is common in CA-MRSA 
(Forcade et al. 2011). 
Clindamycin is commonly associated with gastrointestinal side 
effects. Most common were reports of diarrhea and pseudo-
membranous colitis (PMC). In a study comparing gastrointestinal 
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effects caused by clindamycin and ampicillin, another medication 
known to have gastrointestinal side effects, it was found that 
29.8% of patients developed diarrhea following clindamycin ther-
apy. Patients were evaluated for side effects for six weeks follow-
ing discontinuance of clindamycin therapy (Lusk et al. 1977). 
The findings of a study involving a retrospective chart review 
to compare the efficacy of vancomycin to the efficacy of clin-
damycin indicated that vancomycin and clindamycin had similar 
treatment results (Frei et al. 2010). In some cases, clindamycin is 
used in conjunction with vancomycin as a combination antimi-
crobial therapy. However, it has been reported that clindamycin 
often “antagonizes the antistaphylococcol activity of vancomy-
cin” (Deresinski, 2009). 
Trimethoprim-Sulfamethoxazole
Trimethoprim-Sulfamethoxazole (TMP-SMX) is another anti-
biotic that is used for the treatment of MRSA. TMP-SMX is 
the most commonly prescribed oral antibiotic for outpatient 
treatment of CA-MRSA infections, in addition to clindamycin 
(Forcade et al., 2011; Johnson, Decker, 2008). TMP-SMX is a 
two part drug consisting of one part trimethoprim to five 
parts sulfamethoxazole. The interaction of these two drugs 
inhibits the bacterial synthesis of tetrahydrofolic acid, which 
is used in the production of bacterial nucleic acid.  TMP-SMX 
inhibits two consecutive steps in the formation of folic acid. 
Sulfonamides inhibit dihydropteroate synthetase (DHPS), 
which is responsible for para-aminobenzoic acid to be cata-
lyzed into dihydrofolate. TMP inhibits dihydrofolate reductase 
(DHFR) which causes dihydrofolate to be catalyzed into tet-
rahydrofolate (Huovinen, 2001; Michalek et al., 2015).   TMP-
SMX has also been shown to have anti-inflammatory and 
immunomodulatory effects, enhancing its antimicrobial capa-
bilities (Michalek et al., 2015).
Resistance to TMP-SMX can be found against both drugs, 
trimethoprim and sulfonamides, with different mechanisms 
against each. Resistance of S. aureus to TMP is suspected of 
being caused by a single amino acid change in the dhfr gene, al-
tering DHFR. A single amino acid mutation in the dhps gene is 
responsible for sulfonamide resistance of S. aureus (Huovinen, 
2001). However, a study performed in three cities in the 
United States in 2005, showed that 97% of CA-MRSA isolates 
were susceptible to TMP-SMX (Johnson et al., 2008; Popovich 
et al, 2008). 
TMP-SMX is most commonly administered orally with the 
standard dose of 160/800 mg twice daily for 7-15 days. TMP-
SMX can also be administered intravenously with a dosage of 
trimethoprim (80 mg)/sulfamethoxazole (400 mg) per 5 ml to 
be given as 5 mg/kg every 6-12 hours (Michalek et al., 2015; 
Popovich et al., 2008). TMP-SMX has a high bioavailability, at 
around 85% for both complexes (Stein et al., 2016). Some rec-
ommend a higher dosage, 320/1600 mg twice daily for 7-15 days, 
of oral TMP-SMX to treat SSTI caused by MRSA. Yet Cadena 
et al. found that patients treated with the two different doses 
had similar clinical results. For the treatment of SSTI caused by 
MRSA, a higher dose may not be necessary (2011). A lower dose 
may also minimize gastrointestinal adverse effects (Michalek et 
al., 2015). In studies testing TMP-SMX patients were found to 
have side effects of diarrhea, nausea, vomiting, pruritus, and rash 
(Miller et al., 2015). 
Studies comparing TMP-SMX to clindamycin, show TMP-SMX to 
be a comparable treatment option (Frei et al., 2010; Miller et al., 
2015). TMP-SMX can be used in combination with clindamycin 
to treat pediatric patients (Stein et al., 2016). TMP-SMX bacteri-
cidal activity against MRSA was greater than that of linezolid, ri-
fampicin, and clindamycin, other popular oral antibiotics used to 
treat MRSA. The use of TMP-SMX is economically beneficial as 
well. When compared to linezolid, at $1352 for a 10-day course 
of treatment, TMP-SMX is significantly cheaper, costing only 
$18 for a 10 day course. These numbers are average wholesale 
numbers in the United States (Kaka et al. 2006). According to 
Johnson et al. studies comparing the effectiveness of TMP-SMX 
to vancomycin, the leading drug, are lacking (2008). However, all 
VISA strains in the United States are susceptible to TMP-SMX, 
and TMP-SMX has been used, in combination with other drugs, 
in its treatment (Cosgrove et al., 2004).
Conclusion
Staphylococcus aureus is the leading cause for SSTI in the world. 
In an effort to combat this growing concern, many antimicrobial 
agents have been used. The method of defense was penicillin 
and then methicillin which lead to what is commonly known 
as MRSA. Initially found only in hospitals and other healthcare 
facilities, MRSA soon spread to the community at large. Patients 
with no previous healthcare exposure were now susceptible to 
MRSA. These infections are typically manifested as SSTI in the 
form of impetigo, cellulitis, folliculitis, and abscess. 
With the rise of methicillin resistance, and subsequently re-
sistance to all β-lactam antibiotics, new treatment options 
were needed. Vancomycin became the treatment option of 
choice. However, vancomycin resistance was soon reported as 
well, though not to the extent of methicillin resistance. Other 
antibiotics are also used to combat SSTI caused by MRSA. 
Daptomycin, a newer drug that is administered intravenous-
ly, shows great promise. Linezolid, can be administered both 
parenterally and orally, and therefore has potential to shorten 
hospital stay. Clindamycin and TMP-SMX are both popular oral 
drugs used in outpatient treatment of MRSA. 
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Regardless of the effectiveness and benefits of these non-β-lac-
tam antibiotics, vancomycin remains the “gold standard” of 
treatment therapy for MRSA. Fear of developing resistance 
to alternative drugs limits the extent of their use and keeps 
vancomycin as the leading choice. Healthcare professionals and 
researchers need to remain alert to any signs of resistance of 
antimicrobial agents to prevent its spread and to help stop the 
increased presence of MRSA in hospitals and the community.
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